Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

11.21
-0.1600-1.41%
Post-market: 11.210.00000.00%16:57 EDT
Volume:52.38K
Turnover:586.89K
Market Cap:290.95M
PE:-6.48
High:11.53
Open:11.50
Low:10.95
Close:11.37
Loading ...

Cartesian Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
16 Jun

Cartesian Therapeutics announces employment inducement grants

TIPRANKS
·
03 Jun

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

TIPRANKS
·
31 May

Cartesian Therapeutics Enrolls First Participant in Phase 3 Myasthenia Gravis Study

MT Newswires Live
·
31 May

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 Aurora Trial of Descartes-08 in Patients With Myasthenia Gravis

THOMSON REUTERS
·
30 May

H.C. Wainwright Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

TIPRANKS
·
19 May

Cartesian Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
09 May

Buy Rating for Cartesian Therapeutics: Promising Clinical Progress and Stable Financial Outlook

TIPRANKS
·
09 May

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

TIPRANKS
·
08 May

Cartesian Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Cartesian Therapeutics Q1 EPS $(0.68) Beats $(0.71) Estimate, Sales $1.10M Beat $785.71K Estimate

Benzinga
·
08 May

Cartesian Therapeutics Net Loss $17.7 Mln, or $0.68 Net Loss per Share (Basic) in Q1

THOMSON REUTERS
·
08 May

Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 in Mg Expected 2Q25 - SEC Filing

THOMSON REUTERS
·
08 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 May

Cartesian Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview

Reuters
·
02 May

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire
·
02 May

Cartesian Therapeutics management to meet with BTIG

TIPRANKS
·
25 Apr

Major Investment Alert: Director Buys Big in Cartesian Therapeutics!

TIPRANKS
·
12 Apr

Buy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile

TIPRANKS
·
10 Apr

Cartesian Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
09 Apr